October 21, 2017

Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

Allergy
POSITION PAPER
P. W. Hellings, L. Klimek, C. Cingi, I. Agache, C. Akdis, C. Bachert, J. Bousquet, P. Demoly, P. Gevaert, V. Hox, C. Hupin, L. Kalogjera, F. Manole, R. Mösges, J. Mullol, N. B. Muluk, A. Muraro, N. Papadopoulos, R. Pawankar, C. Rondon, M. Rundenko, S. F. Seys, E. Toskala, L. Van Gerven, L. Zhang, N. Zhang, W. J. Fokkens

Abstract

This EAACI position paper aims at providing a state-of-the-art overview on nonallergic rhinitis (NAR). A significant number of patients suffering from persistent rhinitis are defined as nonallergic noninfectious rhinitis (NANIR) patients, often denominated in short as having NAR. NAR is defined as a symptomatic inflammation of the nasal mucosa with the presence of a minimum of two nasal symptoms such as nasal obstruction, rhinorrhea, sneezing, and/or itchy nose, without clinical evidence of endonasal infection and without systemic signs of sensitization to inhalant allergens.

October 5, 2017

October 2, 2017

Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations

Allergy Asthma Immunol Res. 2017 Nov;9(6):477-482. https://doi.org/10.4168/aair.2017.9.6.477 
Allen P. Kaplan
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC, USA.

Correspondence to: Allen P. Kaplan, MD, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, 171 Ashley Avenue, Charleston, SC 29425, USA. Tel: +1-843-729-0264; Fax: +1-843-722-1253; Email: kaplana@musc.edu 
Abstract

The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H1-receptor blockers are typically employed up to 4 times a day.

Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis


Authors

  • DOI: 10.1111/all.13213  View/save citation
  • Abstract
    Background
    Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term efficacy. However, there are few real-life data on the progression of AR and/or AA in patients receiving AIT.

Oral Allergy Syndrome (Pollen-Food Allergy Syndrome)

Price, Alexandra MS*; Ramachandran, Sarika MD; Smith, Gideon P. MD, PhD; Stevenson, Mary L. MD; Pomeranz, Miriam K. MD; Cohen, David E. MD, MPH

doi: 10.1097/DER.0000000000000087
Reviews
Oral allergy syndrome (OAS) or pollen-food allergy syndrome (PFS) is a hypersensitivity reaction to plant-based foods, manifesting most commonly with pruritus of the lips, tongue, and mouth. Unlike simple food allergy, OAS requires prior sensitization to a cross-reacting inhalant allergen rather than direct sensitization to a specific food protein. In this review, we summarize the clinical features and pathophysiology of OAS and provide an overview of known pollen-food associations.
Full text     PDF

September 28, 2017

Molecular aspects of allergens in atopic dermatitis


Abstract

Purpose of review
Molecular allergology uses pure, mainly recombinant and structurally defined allergen molecules and allergen-derived epitopes to study mechanisms of IgE-associated allergy, to diagnose, and even predict the development of allergic manifestations and to treat and prevent IgE-associated allergies.

Fatal Anaphylaxis: Mortality Rate and Risk Factors

Up to 5% of the US population has suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable.

September 27, 2017

Multicenter prevalence of anaphylaxis in clinic-based oral food challenges

Abstract

Background

Although previous single-center studies report the rate of anaphylaxis for oral food challenges (OFCs) as 9% to 11%, little is known regarding the epidemiology of clinical OFCs across multiple centers in the United States.

Allergists on Social Media